CES1 and malignant colon neoplasm: Zhang et al. (2020) reported that immune genes such as CES1 and CSAG1 could be used as biomarkers for predicting the effects of immunotherapy through a multi-omics analysis. Similarly, Pan et al. (2019) discovered that Laylin is a prognostic marker of survival and is associated with immune infiltration in gastric and colon cancer.